NOG antibody

Catalog No. ABIN1737420

Product Details anti-NOG Antibody

Target: NOG (Noggin (NOG))

Reactivity: Human, Mouse, Rat

Host: Rabbit

Clonality: Polyclonal

Conjugate: This NOG antibody is un-conjugated

Application: Western Blotting (WB)

Specificity: Reacts with human Noggin

Cross-Reactivity: Mouse (Murine)

Cross-Reactivity (Details): Cross reacts with mouse and rat.

Purification: Antigen affinity purified

Immunogen: Synthetic peptide comprising an internal sequence of the human Noggin protein. Sequence is 100% conserved in rat and mouse.

Isotype: IgG

Application Details

Application Notes:

Working dilution: Optimal dilution should be determined by the end user.
The following are guidelines only:
- WB :1/1 000 to 1/2 000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: PBS, Sodium azide 0.02 %

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C/-20 °C

Storage Comment: Short term storage at +4°C. For extended periods store in aliquots at -20°C. Antibodies are guaranteed for 6 month from date of receipt.

Expiry Date: 6 months

Target Details for NOG

Target: NOG (Noggin (NOG))

Alternative Name: Noggin (NOG Products)

Synonyms: SYM1 antibody, SYNS1 antibody, nog-A antibody, nog1 antibody, noggin-1 antibody, noggin antibody, noggin antibody, noggin L homeolog antibody, noggin protein antibody, NOG antibody, Nog antibody, nog.L antibody, noggin antibody

Background: Noggin is involved in numerous developmental processes, such as neural tube fusion and joint formation. The morphogenesis of organs is initiated by a downgrowth from a layer of epithelial stem cells. This process is achieved through the receipt of signals from 1) a WNT protein (WNT3A) to stabilize beta-catenin, and 2) Noggin, which is a bone morphogenetic protein inhibitor. Noggin mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) have been identified, which have multiple joint fusion as their principal defect.

Pathways: Stem Cell Maintenance, Tube Formation